Bio-Techne
| Company type | Public |
|---|---|
| Industry |
|
| Founded | 1976 |
| Founder | Dr. Roger C. Lucas |
| Revenue | $358M (2014)[1] |
| Website | Bio-Techne |
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. For example, it is the parent company of Research and Diagnostic Systems Inc.[2] It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company was co-founded by Dr. Roger C. Lucas, who presently serves as its Chief Scientific Advisor.[3]
It is listed on the NASDAQ under the ticker symbol TECH.[4] Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...",[5] a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch.[6] Interviewing investor Edward B. White for the New York Times, Carole Gould noted that White thought the chief executive, Thomas Oland, was a "deeply committed scientist."[7]
The company's products are used in both clinical and research contexts.[8][9]
Acquisitions
- 2013: Bionostics for $104 million[10]
- 2014: Novus Biologicals for $60 million,[11] ProteinSimple for $300 million[12]
- 2016: Zephyrus Biosciences[13]
References
- ^ BIO-TECHNE Corp at SEC EDGAR
- ^ "Amgen Inc. Sells Its Stake in Techne Corp". Los Angeles Times. 1998-05-12. Retrieved 2015-04-25.
Techne is the parent company for Research and Diagnostic Systems Inc.
- ^ "Roger C. Lucas Ph.D.: Executive Profile & Biography - Businessweek". Businessweek.com. Retrieved 2015-04-25.
Dr. Roger C. Lucas, Ph.D. co-founded Techne Corp., in 1985 and serves as its Chief Scientific Advisor.
- ^ "Bio-Techne Corp". Yahoo! Finance. Retrieved 2015-04-25.
- ^ Reese, John P. (13 October 2010). "China Picks Buffett Might Like". Forbes. Retrieved 2015-04-25.
TECHNE's management also appears to be doing a solid job
- ^ Doorn, Philip van (2015-03-02). "These are the most profitable Nasdaq biotech companies". Dow Jones MarketWatch. Retrieved 2015-04-25.
Bio-Techne Corp
- ^ Carole Gould (2000-09-03). "Investing With: Edward B. White". New York Times. Retrieved 2015-04-25.
praising the chief executive, Thomas Oland, as a "deeply committed scientist."
- ^ Meguru Miyamoto, Kazuyuki Ishihara, and Katsuji Okuda (April 2006). "The Treponema denticola Surface Protease Dentilisin Degrades Interleukin-1β (IL-1β), IL-6, and Tumor Necrosis Factor Alpha". Infect Immun. 74 (4): 2462–2467. doi:10.1128/IAI.74.4.2462-2467.2006. PMC 1418930. PMID 16552080.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ C-C Chang; et al. (2012-11-23). "CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation". Cell Death and Differentiation. 20: 443–455. doi:10.1038/cdd.2012.136. Retrieved 2015-04-25.
- ^ Associated Press (2013-06-18). "Techne to buy Bionostics for $104m in cash". Boston Globe. Retrieved 2015-04-25.
buy Bionostics Holdings Ltd. and its operating subsidiary Bionostics Inc. for $104 million in cash.
- ^ "Bio-Techne Announces Agreement To Acquire Novus Biologicals". Bio-Techne (Press release). 2014-07-02. Retrieved 2015-04-25.
- ^ "Bio-Techne Announces ProteinSimple Acquisition Completion". bio-techne.com (Press release). 2014-08-01. Retrieved 2015-04-27.
- ^ http://www.genengnews.com/gen-news-highlights/bio-techne-acquires-zephyrus-biosciences/81252501/
External links
- Business data for Bio-Techne Corporation:
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |